Health insurance; limit on cost-sharing payments for prescription drugs under certain plans.
Impact
The implementation of SB161 will have a significant effect on consumer healthcare costs, as it directly addresses rising prescription drug expenses. By establishing a cap on cost-sharing amounts, the bill aims to reduce the financial burden on individuals seeking essential medications, particularly for those enrolled in high-deductible health plans. The provisions of the bill will apply to all relevant insurance policies in Virginia starting January 1, 2028, indicating a move towards more consumer-friendly health insurance standards.
Summary
SB161 is a legislative bill aimed at regulating cost-sharing payments for prescription drugs within health insurance plans in Virginia. The bill mandates that any carrier offering a health plan in the individual or small group market must limit out-of-pocket costs for prescription medications based on the coverage tier. Specifically, it stipulates that cost-sharing payments should not exceed set amounts for different levels of coverage—$150 for platinum, $200 for gold, $250 for silver, and $300 for bronze plans per 30-day supply. This provision intends to make prescription medications more affordable for policyholders.
Sentiment
General sentiment towards SB161 appears to be supportive, particularly among advocates for affordable healthcare. Proponents praise the bill for aiming to enhance healthcare access through lower out-of-pocket expenses for vital medications, potentially leading to better health outcomes. Although discussions are not detailed, it can be inferred from the voting history that there is considerable support for this bill as it passed with a significant majority in the legislature.
Contention
While there is strong support for SB161 aimed at improving affordability in healthcare, potential contention may arise regarding how these cost-sharing limits affect insurance carriers and their ability to design flexible health plans. Some industry stakeholders may express concerns that these caps could impact the overall structure of health insurance products offered in Virginia, leading to debates about balance between consumer protection and market flexibility.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.